Aclarion vs YD Bio
ACON and YDES side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACON and YDES compare
Aclarion grew revenue faster over the last twelve months (46.0% versus 16.9% for YD Bio).
YD Bio keeps more of each dollar of sales as profit, with a net margin of −1393% compared with −10260% at Aclarion.
Aclarion scores higher on the StockData Score (8 against 5 for YD Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACON | YDES |
|---|---|---|
| Size and price | ||
| Market cap | $4.7M | – |
| Share price | $1.63 | $6.15 |
| Change, 1 year | −77.5% | −29.1% |
| Change, 5 years | – | −39.5% |
| Beta (5Y) | 0.77 | 0.14 |
| Employees | 11 | 13 |
| StockData Score | ||
| Total score | 8 (better) | 5 |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 47.7× | – |
| P/B | 0.3× | – |
| Growth | ||
| Revenue growth (TTM) | 46.0% (better) | 16.9% |
| Profitability | ||
| Gross margin | 29.1% (better) | 28.1% |
| Operating margin | −10789% | −883% (better) |
| Net margin | −10260% | −1393% (better) |
| FCF margin | – | −1347% |
| Return on equity | −74.1% (better) | −174% |
| Return on invested capital | −959% | −130% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 14.17 (better) | 5.23 |
| Altman Z-score | −4.34 | – |
| Piotroski F-score | 6 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −33.4% | – |
| Shareholder yield | −33.4% | – |
| Ownership | ||
| Held by institutions | 9.0% | – |
| Held by insiders | 16.4% | 92.8% |
| Insider net buying, 12 months | $177K (better) | $129K |
Go deeper
- ACON stock overview
- ACON income statement
- ACON valuation and score
- YDES stock overview
- YDES income statement
- YDES valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.